BofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating while lowering estimates and his price target on Seattle Genetics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE